Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical Trial
Background: We sought to evaluate the efficacy and safety of the different trade forms of streptokinase available in our country, namely Heberkinasa (Heberbiotec, Havana, Cuba) and Streptase (Aventis Behring GmbH, Marburg, Germany). Methods: We conducted a double-blind randomized clinical trial to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2009-01-01
|
| Series: | Journal of Tehran University Heart Center |
| Subjects: | |
| Online Access: | https://jthc.tums.ac.ir/index.php/jthc/article/view/116 |
| _version_ | 1828427981558644736 |
|---|---|
| author | Mojtaba Salarifar Saeed Sadeghian Ali Abbasi Gholamreza Davoodi Alireza Amirzadegan Seyed Kianoosh Hosseini Navid Paydari Aida Biria Parisa Moemeni |
| author_facet | Mojtaba Salarifar Saeed Sadeghian Ali Abbasi Gholamreza Davoodi Alireza Amirzadegan Seyed Kianoosh Hosseini Navid Paydari Aida Biria Parisa Moemeni |
| author_sort | Mojtaba Salarifar |
| collection | DOAJ |
| description | Background: We sought to evaluate the efficacy and safety of the different trade forms of streptokinase available in our country, namely Heberkinasa (Heberbiotec, Havana, Cuba) and Streptase (Aventis Behring GmbH, Marburg, Germany).
Methods: We conducted a double-blind randomized clinical trial to compare the two streptokinase formulations, i.e. Heberkinasa (HBK) or Streptase (STP), in patients with acute myocardial infarction who needed thrombolysis. Thrombolysis success was evaluated angiographically and/or clinically. Clinical follow-up was done 30 days after thrombolysis.
Results: We randomly allocated 221 patients with a mean age of 56.9±10.8 years (males: 88.2%) to HBK (n=119) and STP (n=102) groups. Baseline clinical and demographic characteristics were similar between the two groups, and the two groups were not significantly different in terms of door-to-needle and pain-to-needle intervals. The rate of complications was not significantly different between the groups (44.1% [HBK] vs. 42% [STP]). Angiography was done for 158 (71.5 %) patients in the first 24 hours (9%) and in the first 72 hours (38.8%) after thrombolysis. Lesion morphology and lesion/patient ratio were not significantly different between the two groups (1.87[HBK] vs. 1.67[STP]). The two groups were similar with respect to angiographic patency rate (67.5% [HBK] vs. 67.6% [STP]). The study groups were also similar as regards clinical outcome and complications of both streptokinase formulations.
Conclusion: The present study demonstrated that Heberkinasa is as effective and as safe as a standard streptokinase, namely Streptase, in a clinical setting. |
| first_indexed | 2024-12-10T17:11:04Z |
| format | Article |
| id | doaj.art-c234fc9098b54741ad4fa4f5b9ca6d06 |
| institution | Directory Open Access Journal |
| issn | 1735-8620 2008-2371 |
| language | English |
| last_indexed | 2024-12-10T17:11:04Z |
| publishDate | 2009-01-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Journal of Tehran University Heart Center |
| spelling | doaj.art-c234fc9098b54741ad4fa4f5b9ca6d062022-12-22T01:40:19ZengTehran University of Medical SciencesJournal of Tehran University Heart Center1735-86202008-23712009-01-0141114Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical TrialMojtaba Salarifar0Saeed Sadeghian1Ali Abbasi2Gholamreza Davoodi3Alireza Amirzadegan4Seyed Kianoosh Hosseini5Navid Paydari6Aida Biria7Parisa Moemeni8Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Background: We sought to evaluate the efficacy and safety of the different trade forms of streptokinase available in our country, namely Heberkinasa (Heberbiotec, Havana, Cuba) and Streptase (Aventis Behring GmbH, Marburg, Germany). Methods: We conducted a double-blind randomized clinical trial to compare the two streptokinase formulations, i.e. Heberkinasa (HBK) or Streptase (STP), in patients with acute myocardial infarction who needed thrombolysis. Thrombolysis success was evaluated angiographically and/or clinically. Clinical follow-up was done 30 days after thrombolysis. Results: We randomly allocated 221 patients with a mean age of 56.9±10.8 years (males: 88.2%) to HBK (n=119) and STP (n=102) groups. Baseline clinical and demographic characteristics were similar between the two groups, and the two groups were not significantly different in terms of door-to-needle and pain-to-needle intervals. The rate of complications was not significantly different between the groups (44.1% [HBK] vs. 42% [STP]). Angiography was done for 158 (71.5 %) patients in the first 24 hours (9%) and in the first 72 hours (38.8%) after thrombolysis. Lesion morphology and lesion/patient ratio were not significantly different between the two groups (1.87[HBK] vs. 1.67[STP]). The two groups were similar with respect to angiographic patency rate (67.5% [HBK] vs. 67.6% [STP]). The study groups were also similar as regards clinical outcome and complications of both streptokinase formulations. Conclusion: The present study demonstrated that Heberkinasa is as effective and as safe as a standard streptokinase, namely Streptase, in a clinical setting.https://jthc.tums.ac.ir/index.php/jthc/article/view/116StreptokinaseThrombolytic therapyMyocardial infarction |
| spellingShingle | Mojtaba Salarifar Saeed Sadeghian Ali Abbasi Gholamreza Davoodi Alireza Amirzadegan Seyed Kianoosh Hosseini Navid Paydari Aida Biria Parisa Moemeni Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical Trial Journal of Tehran University Heart Center Streptokinase Thrombolytic therapy Myocardial infarction |
| title | Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical Trial |
| title_full | Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical Trial |
| title_fullStr | Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical Trial |
| title_full_unstemmed | Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical Trial |
| title_short | Efficacy of Two Streptokinase Formulations in Acute Myocardial Infarction: A Double-Blind Randomized Clinical Trial |
| title_sort | efficacy of two streptokinase formulations in acute myocardial infarction a double blind randomized clinical trial |
| topic | Streptokinase Thrombolytic therapy Myocardial infarction |
| url | https://jthc.tums.ac.ir/index.php/jthc/article/view/116 |
| work_keys_str_mv | AT mojtabasalarifar efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT saeedsadeghian efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT aliabbasi efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT gholamrezadavoodi efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT alirezaamirzadegan efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT seyedkianooshhosseini efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT navidpaydari efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT aidabiria efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial AT parisamoemeni efficacyoftwostreptokinaseformulationsinacutemyocardialinfarctionadoubleblindrandomizedclinicaltrial |